Becton, Dickinson and Company (NYSE:BDX) Price Target Cut to $175.00 by Analysts at Stifel Nicolaus

Becton, Dickinson and Company (NYSE:BDX) had its price target lowered by Stifel Nicolaus from $215.00 to $175.00 in a research note released on Thursday,MarketScreener reports.

BDX has been the subject of several other reports. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Barclays began coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price target for the company. Finally, TD Cowen decreased their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $184.71.

Becton, Dickinson and Company Stock Down 2.9%

Shares of Becton, Dickinson and Company stock traded down $4.44 during trading on Thursday, hitting $148.82. 834,915 shares of the stock traded hands, compared to its average volume of 2,811,416. The firm has a market cap of $42.38 billion, a P/E ratio of 24.27, a price-to-earnings-growth ratio of 10.32 and a beta of 0.22. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The stock’s fifty day simple moving average is $158.49 and its 200 day simple moving average is $181.08.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its board has approved a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 1,102 shares of company stock valued at $198,909 in the last three months. 0.40% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

Hedge funds have recently made changes to their positions in the company. Auto Owners Insurance Co grew its stake in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares during the period. Wellington Management Group LLP lifted its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after purchasing an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $734,321,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q2 results beat analyst expectations — adjusted EPS of $2.90 vs. $2.77 consensus and revenue of $4.71B vs. $4.67B, driven by broad segment strength and improved margins. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Company raised full‑year adjusted EPS guidance to $12.52–$12.72 (slightly above consensus) and raised its annual profit forecast, citing strength in drug‑delivery devices and surgical equipment — a key driver of the rally. Becton Dickinson raises annual profit forecast on strength in drug delivery devices
• Positive Sentiment: Significant capital allocation moves: executed a $2.0B accelerated share repurchase (ASR) and retired $2.1B of debt in the quarter — supports EPS per share and reduces leverage. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management change announced — Vitor Roque named CFO effective May 7, providing leadership clarity after the quarter. BD Appoints Vitor Roque Chief Financial Officer
• Neutral Sentiment: Company reaffirmed low‑single‑digit revenue growth for FY‑2026 — indicates modest top‑line expansion even as margins and EPS outlook improve. BD forecasts FY 2026 adjusted EPS of $12.52-$12.72 while reaffirming low-single-digit revenue growth
• Neutral Sentiment: Options flow shows elevated activity that some services interpret as bets on near‑term volatility or a price move — worth watching but not a fundamental driver yet. Is the Options Market Predicting a Spike in Becton Dickinson Stock?
• Negative Sentiment: GAAP EPS and adjusted EPS remain lower year‑over‑year (prior-year EPS was $3.35 vs. $2.90 this quarter), signaling some profit pressure despite the beat — a caution for longer‑term growth expectations. Becton, Dickinson and Company earnings report

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.